Galectin-3 is a member of a
beta-galactoside-binding
animal lectin family. Previous in vitro studies have demonstrated that
galectin-3 is involved in a number of activities; however, the roles of this
lectin in physiological and
pathological processes in vivo remain to be elucidated. Herein, we show, in a murine model of
ovalbumin (OVA)-induced
asthma that 1) peribronchial inflammatory cells expressed large amounts of
galectin-3; 2) bronchoalveolar lavage fluid from OVA-challenged mice contained significantly higher levels of
galectin-3 compared to control mice; and 3) macrophages in bronchoalveolar lavage fluid were the major cell type that contained
galectin-3. We investigated the role of
galectin-3 in the allergic airway response by comparing
galectin-3-deficient (gal3(-/-)) mice and wild-type (gal3(+/+)) mice. OVA-sensitized gal3(-/-) mice developed fewer eosinophils and lower goblet cell
metaplasia, after airway OVA challenge compared to similarly treated gal3(+/+) mice. In addition, the OVA-sensitized gal3(-/-) mice developed significantly less
airway hyperresponsiveness after airway OVA challenge compared to gal3(+/+) mice. Finally, gal3(-/-) mice developed a lower Th2 response, but a higher Th1 response, suggesting that
galectin-3 regulates the Th1/Th2 response. We conclude that
galectin-3 may play an important role in the pathogenesis of
asthma and inhibitors of this
lectin may prove useful for treatment of this disease.